Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program - 26/02/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Funding sources: Dr Lacouture is funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30-CA-008748. |
|
Conflicts of interest: Dr Lacouture has a consultant/speaking role with Legacy, Adgero, Amryt, Celldex, Debiopharm, Galderma, Johnson and Johnson, Novocure, Merck Sharp and Dohme, Helsinn, Janssen, Menlo, Novartis, F. Hoffmann-La Roche AG, AbbVie Inc, Boehringer Ingelheim, Allergan, Amgen, E.R. Squibb & Sons LLC, EMD Serono, AstraZeneca, Genentech, LEO Pharma, Loxo, Oncoderm, Seattle Genetics, Bayer, Lutris, Pierre Fabre, Paxman Coolers, Biotechspert, Teva, Parexel, OnQuality, Harborside, Wiley, Azitra, ADC Therapeutics, QED, NCODA, Apricity, and Takeda Millenium. Dr Lacouture also receives research funding from Berg, Lutris, Paxman, Novocure, Johnson and Johnson, US Biotest, and Veloce. Drs Jimenez, Gwillim, Figuerido, Rangel, Choi, West, and Cory Kosche and Corrine Rauck have no conflicts of interest to declare. |
|
IRB approval status: The Northwestern University Institutional Review Board approved the study. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?